A. Sinclair Dunlop, Director at Apellis Pharmaceuticals, Inc. (APLS), sold 74,000 shares at $39.63 ($2.9M) on 2024-06-21, disclosed to the SEC on 2024-06-21.
Open-market sale of $2.9M APLS by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $39.22 | 35,305 | $1.4M | 47.7% |
| 2 | $39.22 | 35,305 | $1.4M | 47.7% |
| 3 | $39.63 | 1,695 | $67K | 2.3% |
| 4 | $39.63 | 1,695 | $67K | 2.3% |
| Total | $39.24 avg | 74,000 | $2.9M | 100% |
| Filing → |
| APLS | SELL | 2025-09-19 | $1.4M | — | Filing → |
| APLS | SELL | 2024-09-17 | $2.7M | — | Filing → |
| APLS | SELL | 2024-03-20 | $2.1M | — | Filing → |